Truist reiterates Buy on Revolution Medicines; raises target
Truist maintained a Buy rating on Revolution Medicines and raised its price target to $240 from $239.
Story updates
05:17:38 PM UTC
SquawkNews
Revolution Medicines Price Target Raised to $240.00/Share From $239.00 by Truist Securities